Do urologists adhere to the British National Formulary (BNF) guidelines?—Results of a postal questionnaire survey

References 

1. Woolf SH, Grol R, Hutchinson A, Eccles MP, Grimshaw JM. Clinical practice guidelines: the potential benefits, limitations and harms of recommending how to care for patients. British Medical Journal. 1999;318:527–530
2. McGlynn EA, Asch SM, Adams J, Keesey J, Hicks J, DeCristofaro , et al. The quality of health care delivered to adults in the United States. New England Journal of Medicine. 2003;348:2635–2645
3. British National Formulary BNF 55. March 2008.
4. British National Formulary BNF 53. March 2007.
5. British National Formulary. Metformin hydrochloride. Available from: http://www.bnf.org/bnf/bnf/current/4186.htm [accessed 16 July 2007].
6. Prostate cancer and gonadorelin analogues. British National Formulary BNF 55. 8.3.4.2: 486.
7. Gould FK, Elliott TSJ, Foweraker J, Fulford M, Perry JD, Roberts GJ, et al. Guidelines for the prevention of endocarditis: report of the working party of the British society for antimicrobial chemotherapy. Journal of Antimicrobial Chemotherapy. 2006;57:1035–1042
8. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis. Circulation. 2007;115:1–19
9. Strom BL, Abrutyn E, Berlin J, Kinman J, Feldman RS, Stolley PD, et al. Risk factors for infective endocarditis: oral hygiene and nondental exposures. Circulation. 2000;102:2842–2848
10. The Royal College of Radiologists. Standards for iodinated intravascular contrast agent administration to adult patients. Available from: http://www.rcr.ac.uk/docs/radiology/pdf/IVcontrastPrintFinal.pdf [accessed 16 July 2007].
11. Thomsen HS, Morcos SK. Contrast media and metformin: guidelines to diminish the risk of lactic acidosis in non-insulin dependent diabetics after administration of contrast media. European Radiology. 1999;9:738–740
    • MEDLINE
    • CrossRef
12. Nawaz S, Cleveland T, Gaines PA, Chan P. Clinical risk associated with contrast angiography in metformin treated patients: a clinical review. Clinical Radiology. 1998;53:342–344
    • Abstract
    • Full-Text PDF (348 KB)
    • CrossRef
13. Tiselius H-G, Ackermann D, Alken P, Buck C, Conort P, Gallucci M, et al. Urolithiasis. Metformin. 3.1.2. European Association of Urology guidelines.
14. Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharmacological Research. 1994;30:187–228
15. McCartney MM, Gilbert FJ, Murchison LE, Pearson D, McHardy K, Murray AD. Metformin and contrast media—a dangerous combination?. Clinical Radiology. 1999;54:29–33
    • Abstract
    • Full-Text PDF (515 KB)
    • CrossRef
16. Pond GD, Smyth SH, Roach DJ, Hunter G. Metformin and contrast media: genuine risk or witch hunt?. Radiology. 1996;201:879–880
    • MEDLINE
17. Electronic Medicines Compendium. Drogenil. Available from: http://emc.medicines.org.uk/ [accessed 16 July 2007].
18. Aus G, Abbou CC, Bolla M, Heidenreich A, Van Popple H, Schmid A-P, et al. Prostate Cancer. European Association of Urology guidelines. 11.3.1.3.
19. Kuhn J-M, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, et al. Prevention of the transient adverse effects of a gonadotrophin-releasing hormone analogue (buserelin) in metastatic prostate carcinoma by administration of an antiandrogen (nilutamide). New England Journal of Medicine. 1989;321:413–418
20. Yoshida K, Takeuchi S. Pre-treatment with chlormadinone acetate eliminates testosterone surge induced by a luteinising-hormone-releasing hormone analogue and the risk of disease flare in patients with metastatic carcinoma of the prostate. European Urology. 1995;27:187–191
    • MEDLINE
21. Mahler C. Is disease flare a problem?. Cancer. 1993;72:3799–3802
    • MEDLINE
    • CrossRef